Immunosuppressants - Southern Europe

Southern Europe

The Immunosuppressants market in Southern Europe is anticipated to achieve a revenue of US$1.34bn by 2024.
The market is expected to experience a steady annual growth rate (CAGR 2024-2029) of 14.87%, leading to a market volume of US$2.68bn by 2029.
When compared globally, United States is projected to generate the highest revenue of US$35,470.00m in 2024.
In Southern Europe, the demand for immunosuppressants in countries like Italy and Spain has been steadily increasing due to the rising prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Southern Europe has been steadily increasing over the past few years.

Customer preferences: Patients in Southern Europe are increasingly opting for immunosuppressants as a treatment for autoimmune diseases. The rise in organ transplants has also contributed to the growing demand for immunosuppressants in the region.

Trends in the market: Italy is one of the largest markets for immunosuppressants in Southern Europe. The country has a high incidence of autoimmune diseases, which has led to an increased demand for immunosuppressants. Spain and Portugal are also witnessing a rise in the demand for these drugs. The market for immunosuppressants in Greece and Cyprus is relatively small, but it is expected to grow in the coming years.

Local special circumstances: The healthcare systems in Southern Europe are publicly funded, which means that the governments play a significant role in determining the availability and pricing of drugs. In Italy, for example, the government negotiates the prices of drugs with pharmaceutical companies to keep the costs low. This has led to a decrease in the prices of immunosuppressants in the country. In Spain, the government has implemented a reference pricing system, which has also contributed to the affordability of these drugs.

Underlying macroeconomic factors: The aging population in Southern Europe has led to an increase in the incidence of autoimmune diseases. The region is also witnessing a rise in the number of organ transplants, which has further boosted the demand for immunosuppressants. The economic slowdown in the region has led to a decrease in the prices of drugs, which has made these drugs more affordable for patients. However, the ongoing COVID-19 pandemic has disrupted the supply chains of pharmaceutical companies, which has led to a shortage of some immunosuppressants in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.